PCI-32765Catalog No. A11020
Quick Overview
| Catalog Num | A11020 |
|---|---|
| M. Wt | 440.5 |
| Formula | C25H24N6O2 |
| Solubility | DMSO |
| Purity | >98% |
| Storage | at -20°C 2 years |
| CAS No. | 936563-96-1 |
| Synonyms | Ibrutinib |
| Chemical Name | 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one |
| SMILES Code | C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N |
Introduction |
PCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Targets |
|
| Solubility (25C) * | In vitro | DMSO | 88 mg/mL (199.77 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 1% DMSO/30% polyethylene glycol/1% Tween 80 | 12 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
Reference:
[1]. Pan, Z; Scheerens, H; Li, SJ; Schultz, BE; Sprengeler, PA; Burrill, LC; Mendonca, RV; Sweeney, MD; Scott, KC; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T. (2007). “Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase”. ChemMedChem 2 (1): 58–61.
[2]. Honigberg, LA; Smith, AM; Sirisawad, M; Verner, E; Loury, D; Chang, B; Li, S; Pan, Z; Thamm, DH; Miller, RA; Buggy, JJ (2010). “The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy”. Proceedings of the National Academy of Sciences of the United States of America 107 (29): 13075–80.
[3]. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O’Brien S, Chiorazzi N, Burger JA (2012). The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo 119. Blood. pp. 1182–1189.
| Return Policy | Contact information |
| Adooq Bioscience has Satisfaction Guarantee return policy. You may return/exchange any items within 365 days from the original purchase date if you are not satisfied with your purchase, either for protocol related or product related problems. >>This offer is only valid for products purchased directly from Adooq and its authorized distributors. >>Prior to returning any items, please contact the Customer Service (sales@adooq.com) to obtain an Return/Exchange Authorization. Items returned without prior authorization may not be accepted. Any items returned to Adooq should be in the original packaging and in the same condition as originally purchased. |
Website: www.adooq.com Order: sales@adooq.com Phone: (866)930-6790 (US & Canada) +1-323-389-9269 (Outside of US & CAN) Fax: (866)333-9607 (US & Canada) +1-323-606-8156 (Outside of US & CAN) Support: support@adooq.com |